Last verified: 20 August 2026
Why this site exists
In April 2026, FDA removed twelve peptides from a list called Category 2. In July, an FDA advisory committee voted to recommend six of them for compounding. Within days, a large part of the internet was reporting that peptides were legal again.
They are not. The April removal happened because the people who nominated those substances withdrew their nominations, which takes a substance out of FDA's interim framework entirely — a worse position than being listed, not a better one. The July vote was advisory and non-binding, and was taken over FDA staff's own recommendation to reject all seven. Rulemaking has not started. The list that actually governs which bulk substances may be compounded, 21 CFR 216.23, contains six substances and has not been amended since February 2019. None of them is a peptide.
We started this site because we went looking for a plain, accurate, consumer-readable account of that and could not find one. What exists is either marketing copy from companies selling peptides, or law firm client alerts written for pharmacists. The gap in between is where most people actually are.
What we do
We read primary documents and write down what they say. We read companies' prices off their own websites and record the date. We read terms of service, which is tedious and is where the money usually is — the intro rate that becomes a different rate at month seven, the administrative fee charged to people who cancel before a clinician has even looked at their intake, the arbitration clause.
Then we publish it with links, so you can check us.
What we are not
We are not clinicians. We do not diagnose, prescribe, or advise on treatment, and we do not take these substances ourselves. We are consumer researchers, which is a narrower and less impressive thing, and we would rather say so plainly than dress it up.
We are also not neutral about accuracy. We think a market where the central factual claim is wrong nearly everywhere is a market where people get hurt — financially, and sometimes otherwise.
How we pay for it
Affiliate commissions. Some links are affiliate links, labelled (affiliate) inline. No company can pay for inclusion or ranking. The full explanation, including which companies we have declined to link to and why, is on our disclosure page.
Related work
The same team publishes MyGLP1Reviews, which applies the same method to GLP-1 telehealth providers.
Contact
Corrections, tips, and complaints: corrections@getpeptidereviews.com. If you work at a company we have written about and we got something wrong, use that address and we will check it against the source.
This is consumer research about how peptides are regulated and sold. It is not medical advice, and we are not your doctor. Nothing here should be used to start, stop or change any treatment. Talk to a licensed clinician who knows your history.